Delving into the Latest Updates on Chengdu Biostar Pharmaceuticals Ltd. with Synapse

Overview

Tags

Nervous System Diseases

Endocrinology and Metabolic Disease

Respiratory Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	1
Nervous System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

Tubulin	1

主要目的：评价优替德隆胶囊在晚期实体瘤患者中的安全性和耐受性，确定最大耐受剂量和剂量限制性毒性。次要目的：1.评价优替德隆胶囊相对于优替德隆注射液的绝对生物利用度； 2. 评价优替德隆胶囊在晚期实体瘤患者中的药代动力学特征； 3. 初步评价优替德隆胶囊在晚期实体瘤患者中的有效性和安全性； 4. 推荐后续临床试验给药剂量和给药方案。

[Translation]

Primary objectives: To evaluate the safety and tolerability of Utidelon Capsules in patients with advanced solid tumors, and to determine the maximum tolerated dose and dose-limiting toxicity. Secondary objectives: 1. To evaluate the absolute bioavailability of Utidelon Capsules relative to Utidelon Injection; 2. To evaluate the pharmacokinetic characteristics of Utidelon Capsules in patients with advanced solid tumors; 3. To preliminarily evaluate the efficacy and safety of Utidelon Capsules in patients with advanced solid tumors; 4. To recommend the dosage and dosing regimen for subsequent clinical trials.

Start Date16 Aug 2023

Sponsor / Collaborator

Beijing Biostar Pharmaceuticals Co. Ltd.

[+1]

CTR20223015 / RecruitingPhase 3

优替德隆联合AC对比多西他赛联合AC用于HER2阴性早期高危或局部晚期乳腺癌新辅助化疗的Ⅲ期、开放、随机对照研究

[Translation] A phase III, open-label, randomized controlled study of eutilide combined with AC versus docetaxel combined with AC for neoadjuvant chemotherapy of HER2-negative early high-risk or locally advanced breast cancer

评估优替德隆联合多柔比星+环磷酰胺（AC）化疗方案对比多西他赛联合多柔比星+环磷酰胺（AC）方案用于HER2阴性早期高危或局部晚期乳腺癌新辅助化疗的疗效和安全性

[Translation]

To evaluate the efficacy and safety of eutilide combined with doxorubicin + cyclophosphamide (AC) chemotherapy versus docetaxel combined with doxorubicin + cyclophosphamide (AC) chemotherapy for neoadjuvant chemotherapy of HER2-negative early high-risk or locally advanced breast cancer

Start Date25 May 2023

Sponsor / Collaborator

Chengdu Biostar Pharmaceuticals Ltd.

NCT05172518 / Not yet recruitingPhase 3IIT

Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer : A Phase III, Open-label, Randomized Controlled Trial

It is a phase III trial to explore the efficacy and safety of utidelone plus capecitabine versus taxane plus capecitabine in HER2-negative locally advanced or metastatic breast cancer and the differences of metronomic capecitabine and intermittent capecitabine in combination chemotherapy.

Start Date01 Mar 2022

Sponsor / Collaborator

Sun Yat-Sen University

[+1]

100 Clinical Results associated with Chengdu Biostar Pharmaceuticals Ltd.

Login to view more data

0 Patents (Medical) associated with Chengdu Biostar Pharmaceuticals Ltd.

Login to view more data

100 Deals associated with Chengdu Biostar Pharmaceuticals Ltd.

Login to view more data

100 Translational Medicine associated with Chengdu Biostar Pharmaceuticals Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

1

Login to view more data